Eocene (Drug Discovery) Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
EOCN
- Investments
-
2
- Share Price
-
$1.80
- (As of Friday Closing)
Eocene (Drug Discovery) General Information
Description
Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.
Contact Information
Website
www.galmedpharma.comCorporate Office
- 16 Abba Hillel Silver Road
- Ramat Gan 5250608
- Israel
Corporate Office
- 16 Abba Hillel Silver Road
- Ramat Gan 5250608
- Israel
Eocene (Drug Discovery) Stock Performance
As of 20-Nov-2026, Eocene (Drug Discovery)’s stock price is $1.80. Its current market cap is $1.9M with 1.07M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.80 | $1.75 | $1.75 - $10.08 | $1.9M | 1.07M | 18.4K | -$15.21 |
Eocene (Drug Discovery) Financials Summary
As of 30-Jun-2026, Eocene (Drug Discovery) has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (13,727) | (14,939) | (11,854) | (11,490) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (12,245) | (11,223) | (7,937) | (7,256) |
| Net Income | (11,343) | (10,309) | (7,517) | (6,912) |
| Total Assets | 18,283 | 18,627 | 18,500 | 16,629 |
| Total Debt | 129 | 0 | 0 | 41 |
Eocene (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Eocene (Drug Discovery) Comparisons
Industry
Financing
Details
Eocene (Drug Discovery) Competitors (20)
One of Eocene (Drug Discovery)’s 20 competitors is Savara, a Formerly VC-backed company based in Yardley, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Savara | Formerly VC-backed | Yardley, PA | ||||
| Avalyn Pharma | Formerly VC-backed | Boston, MA | ||||
| Novartis | Corporation | Basel, Switzerland | ||||
| Coherus Oncology | Formerly VC-backed | Redwood City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Eocene (Drug Discovery) Signals
Eocene (Drug Discovery) Investments & Acquisitions (2)
Eocene (Drug Discovery)’s most recent deal was a Merger/Acquisition with Colospan for . The deal was made on 22-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Colospan | 22-Jun-2026 | Merger/Acquisition | Surgical Devices | ||
| OnKai | 04-May-2023 | Corporate | Business/Productivity Software |
Eocene (Drug Discovery) ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Eocene (Drug Discovery) Exits (1)
Eocene (Drug Discovery)’s most recent exit was on 04-May-2023 from OnKai. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| OnKai | 04-May-2023 | Completed |
|
Eocene (Drug Discovery) FAQs
-
When was Eocene (Drug Discovery) founded?
Eocene (Drug Discovery) was founded in 2000.
-
Where is Eocene (Drug Discovery) headquartered?
Eocene (Drug Discovery) is headquartered in Ramat Gan, Israel.
-
What is the size of Eocene (Drug Discovery)?
Eocene (Drug Discovery) has 6 total employees.
-
What industry is Eocene (Drug Discovery) in?
Eocene (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Eocene (Drug Discovery) a private or public company?
Eocene (Drug Discovery) is a Public company.
-
What is Eocene (Drug Discovery)’s stock symbol?
The ticker symbol for Eocene (Drug Discovery) is EOCN.
-
What is the current stock price of Eocene (Drug Discovery)?
As of 20-Nov-2026 the stock price of Eocene (Drug Discovery) is $1.80.
-
What is the current market cap of Eocene (Drug Discovery)?
The current market capitalization of Eocene (Drug Discovery) is $1.9M.
-
Who are Eocene (Drug Discovery)’s competitors?
Savara, Avalyn Pharma, Novartis, Coherus Oncology, and Merck & Co. are some of the 20 competitors of Eocene (Drug Discovery).
-
What is Eocene (Drug Discovery)’s annual earnings per share (EPS)?
Eocene (Drug Discovery)’s EPS for 12 months was -$15.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process